- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2018–2023 · research · R01
Immunotherapeutic responses to neoantigens in head and neck cancer
Ravindra Uppaluri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K01
Coordinate roles of histone H3K27me3 and DNA methylation in intestinal homeostasis and tumorigenesis
Unmesh Jadhav · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
Patrick Alexander Ott · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation with Movement to Improve Prognosis in Breast Cancer Survivors
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
Metabolically active macrophages: a novel link between obesity and triple negative breast cancer
Payal Tiwari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · fellowship · Pew Biomedical Scholars Program
Amy S.Y. Lee — Pew Biomedical Scholar (2018)
Amy S.Y. Lee · Dana-Farber Cancer Institute · funded by Pew Charitable Trusts
2018–2022 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · BCRP
Epigenetic Heterogeneity and Targets in Triple-Negative Breast Cancer
Bojana Jovanovic · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2021 · research · R21
Study of Plasma Next Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients with ALK Drug Resistance (SPACEWALK)
Mark M. Awad · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · BCRP
Targeting CDK4/6 in HER2-Positive Breast Cancer Brain Metastasis
Nancy Lin · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2020 · research · R21
Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
Patrick Alexander Ott · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Resistance and Sensitivity to MET Inhibitors in Lung Cancer
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · research · R21
Identifying PTSD in Young Adult Cancer Survivors in the DSM-5 Era: Are Newly Revised PRO Measures Accurate Compared to a Structured Diagnostic Interview?
Christopher John Recklitis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R00
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
Lawrence Fong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · career development · K99
Data-driven approaches to identify biomarkers and regulators of cancer drug resistance
Peng Jiang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · KCRP
Use of Anti-CAIX/CD70 Bispecific CAR T-Cell Factories to Change the Tumor Microenvironment, Mitigate On-Target Off-Tumor Toxicities, and Achieve RCC Cures
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2023 · research · R01
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R01
Comprehensive minimal residual disease tracking in cancer
G. Mike Makrigiorgos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Rochelle Bagatell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R01
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Rochelle Bagatell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · grant · KCRP
Using Single-Cell Transcriptomics to Understand Tumor and Immune Heterogeneity Driving Resistance to Immune Therapy in Advanced RCC
Catherine Wu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2019 · career development · K01
Coordinate roles of histone H3K27me3 and DNA methylation in intestinal homeostasis and tumorigenesis
Unmesh Jadhav · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2029 · cooperative agreement · U24
Human Tumor Atlas Network: Data Coordinating Center
Ethan Cerami · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Immunotherapeutic responses to neoantigens in head and neck cancer
Ravindra Uppaluri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation with Movement to Improve Prognosis in Breast Cancer Survivors
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis
Alessandra Biffi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · grant · Lung Cancer Research Foundation Annual Grant Program
2018 – Lung Cancer Research Foundation Annual Grant Program – Dana-Farber Cancer Institute – Chiara Ambrogio, PhD
Chiara Ambrogio · Dana-Farber Cancer Institute · funded by Lung Cancer Research Foundation
2018–2024 · research · R01
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · grant · PCRP
Molecular and Clinical Correlates with Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy
Himisha Beltran · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2023 · research · R01
NMR-based dynamic assessment of TCR transmembrane conformational states linked to T cell function
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · UH3
Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training
James A. Tulsky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · UM1
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
Michael James Hassett · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · career development · K08
Investigating the Mechanisms of Cohesinopathy in Myelodysplastic Syndromes
Zuzana Tothova · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · grant · DP2
Post-Translational Modification of Protein Surfaces
Justin Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
